IMLYGIC
Biological
Amgen Inc.
Total Payments
$109.4M
Transactions
4,496
Doctors
597
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $554,647 | 23 | 3 |
| 2023 | $2.6M | 27 | 6 |
| 2022 | $3.0M | 104 | 5 |
| 2021 | $13.5M | 345 | 10 |
| 2020 | $15.8M | 464 | 9 |
| 2019 | $23.3M | 643 | 69 |
| 2018 | $22.1M | 1,168 | 280 |
| 2017 | $28.6M | 1,722 | 327 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $108.3M | 2,129 | 99.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $388,976 | 1,002 | 0.4% |
| Consulting Fee | $379,190 | 162 | 0.3% |
| Travel and Lodging | $137,741 | 347 | 0.1% |
| Royalty or License | $115,792 | 6 | 0.1% |
| Food and Beverage | $44,487 | 825 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $26,921 | 22 | 0.0% |
| Education | $47.76 | 3 | 0.0% |
Payments by Type
Research
$108.3M
2,129 transactions
General
$1.1M
2,367 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | Amgen Inc. | $30.3M | 3 |
| AMG 678 CRADA | Amgen Inc. | $21.7M | 0 |
| A phase Ib/II study of talimogene laherparepvec (T-VEC) administered concurrently with the anti-PD1 monoclonal antibody pembrolizumab in patients with metastatic and/or locallyadvanced sarcoma | Amgen Inc. | $10.8M | 0 |
| Neoadjuvant Intralesional Injection of Talimogene Laherparepvec with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft Tissue Sarcomas | Amgen Inc. | $5.7M | 0 |
| T-VEC + Pembrolizumab in patients progressing on prior anti-PD-1 therapy | Amgen Inc. | $4.9M | 0 |
| A Phase 2 Study Using TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB and TRABECTEDIN as First, Second/Third Line Therapy for Advanced Sarcoma, including Desmoid Tumor and Chordoma | Amgen Inc. | $4.1M | 0 |
| P1b/2 Solid Tumor Hepatic Injection Safety. | Amgen Inc. | $3.7M | 0 |
| A Phase 1/2 Study of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | Amgen Inc. | $2.6M | 0 |
| A Phase 1 study of TVEC in combination with paclitaxel, nab-paclitaxel, or endocrine therapy in patients with breast cancer and other solid tumor malignancies who have evidence of locally injectable disease | Amgen Inc. | $2.2M | 0 |
| P1b talimogene laherparepvec + PD-L1 Combo (Agent and Tumor Type (CRC +TNBC) | Amgen Inc. | $2.2M | 1 |
| A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (T-VEC) with or without Radiotherapy for Cutaneous Melanoma or Merkel Cell Carcinoma | Amgen Inc. | $2.0M | 0 |
| A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) | Amgen Inc. | $1.6M | 0 |
| P1b2 talimogene laherparepvec + Yervoy combo melanoma | Amgen Inc. | $1.4M | 7 |
| A phase II study of talimogene laherparepvec (T-VEC) in the treatment of locally advanced cutaneous angiosarcoma | Amgen Inc. | $1.3M | 0 |
| A Pilot Study of Neoadjuvant Talimogene Laherparepvec (TVEC) and Panitumumab in Patients with Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS) | Amgen Inc. | $1.2M | 0 |
| P1b Monotherapy in Pediatric Patients | Amgen Inc. | $1.2M | 0 |
| A phase I study of talimogene laherparepvec administered endoscopically for the treatment of locally advanced or metastatic pancreas cancer refractory to at least one chemotherapy regimen | Amgen Inc. | $1.0M | 0 |
| A Phase II study using a combination of OncoVEX and chemotherapy of physician's choice for triple negative breast cancer (TNBC) or inflammatory breast cancer (IBC) patients with local recurrence | Amgen Inc. | $858,008 | 0 |
| A Single Arm Phase 2 Study of talimogene laherparepvec (T-VEC) in patients with cutaneous squamous cell cancer | Amgen Inc. | $808,780 | 0 |
| P2 Neo-adjuvant melanoma | Amgen Inc. | $650,072 | 1 |
Top Doctors Receiving Payments for IMLYGIC — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , DDS | Student in an Organized Health Care Education/Training Program | Spartanburg, SC | $770.40 | 8 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $767.50 | 1 |
| , MD, PHD | Pediatrics | Richmond, VA | $752.54 | 3 |
| Thomas Gajewski | Hematology & Oncology | Burr Ridge, IL | $750.00 | 2 |
| , MD | Dermatology | Phoenix, AZ | $736.06 | 3 |
| , M.D | Hematology & Oncology | Sacramento, CA | $700.00 | 1 |
| , MD | Surgical Oncology | Chicago, IL | $694.89 | 2 |
| , MD | Surgical Oncology | Brooklyn, NY | $672.75 | 2 |
| , D.O | Hematology | Daytona Beach, FL | $649.87 | 13 |
| , MD | Hematology | Daytona Beach, FL | $649.87 | 13 |
| , M.D | Internal Medicine | Dallas, TX | $649.00 | 1 |
| , M.D | Specialist | Philadelphia, PA | $632.10 | 3 |
| , CRNA | Nurse Practitioner | Knoxville, TN | $620.52 | 6 |
| , M.D | Medical Oncology | Vista, CA | $600.00 | 1 |
| , MD | Internal Medicine | Cincinnati, OH | $572.99 | 5 |
| , M.D | Medical Oncology | Fridley, MN | $538.20 | 1 |
| , M.D | Medical Oncology | Boston, MA | $515.59 | 4 |
| , MD | Surgical Oncology | Tampa, FL | $501.13 | 1 |
| , MD, PHD | Medical Oncology | Seattle, WA | $435.84 | 1 |
| , MD | Hematology & Oncology | Riverside, CA | $386.37 | 5 |
| , PA-C | Physician Assistant | Tampa, FL | $376.50 | 2 |
| , PA | Physician Assistant | Tampa, FL | $376.50 | 1 |
| , MD | Transplant Surgery | New York, NY | $291.00 | 2 |
| , MD | Hematology & Oncology | Riverside, CA | $289.62 | 4 |
| , MD | Surgery | Ann Arbor, MI | $261.13 | 3 |
Ad
Manufacturing Companies
- Amgen Inc. $109.4M
Product Information
- Type Biological
- Total Payments $109.4M
- Total Doctors 597
- Transactions 4,496
About IMLYGIC
IMLYGIC is a biological associated with $109.4M in payments to 597 healthcare providers, recorded across 4,496 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $554,647 was paid across 23 transactions to 3 doctors.
The most common payment nature for IMLYGIC is "Unspecified" ($108.3M, 99.0% of total).
IMLYGIC is associated with 20 research studies, including "P1/3 talimogene laherparepvec + MK-3475 Combo melanoma" ($30.3M).